Background Immunosuppression significantly contributes to treatment failure in nasopharyngeal carcinoma (NPC). Messenger RNA (mRNA) modifications such as methylation and acetylation play crucial roles in immunosuppression. However, N4-acetylcytidine (ac4C), the only acetylation modification event has rarely been studied in NPC. Methods First, clinical tissue samples and nude mouse models were used to explore the expression of… Continue reading Acetyltransferase NAT10 inhibits T-cell immunity and promotes nasopharyngeal carcinoma progression through DDX5/HMGB1 axis
Tag: Cancer Immunotherapy
How cancer cells trick the immune system by altering mitochondria
Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have developed immune evasion strategies, leading to poor treatment responses. Now, researchers have identified the transfer of mitochondria with mutated DNA from cancer cells to immune cells as a key mechanism of immune evasion and resistance to… Continue reading How cancer cells trick the immune system by altering mitochondria
Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy
Abstract Background Alterations in mismatch repair (MMR) genes like MLH1, MSH2, MSH6, and PMS2 can lead to microsatellite instability–high (MSI-H) tumors. These mutations can be inherited, as in Lynch syndrome (LS), or occur de novo. Although immune checkpoint inhibitors (ICI) improves survival in MSI-H colorectal cancer (CRC) compared to chemotherapy, data comparing outcomes for patients with… Continue reading Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy
New mechanism of immune evasion discovered in cancer cells
The immune system plays a key role in detecting and destroying cancer cells. Cancer immunotherapy works by programming immune cells to recognize and eliminate cancer cells. However, many cancers can escape immune surveillance through various mechanisms, resulting in resistance to treatment. This highlights the need to better understand the molecular processes that enable immune evasion. … Continue reading New mechanism of immune evasion discovered in cancer cells
Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy
Abstract Background Alterations in mismatch repair (MMR) genes like MLH1, MSH2, MSH6, and PMS2 can lead to microsatellite instability–high (MSI-H) tumors. These mutations can be inherited, as in Lynch syndrome (LS), or occur de novo. Although immune checkpoint inhibitors (ICI) improves survival in MSI-H colorectal cancer (CRC) compared to chemotherapy, data comparing outcomes for patients with… Continue reading Comparison of survival outcomes for patients with Lynch vs non‐Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy
AlbiCDN： Albumin-binding Amphiphilic STING Agonists Augments the Immune Activity for Cancer Immunotherapy
Stimulator of interferon genes (STING) has been an attractive target in cancer immunother-apy. However, natural ligands cyclic dinucleotides (CDNs) and CDN derivatives have demonstrated limited efficacy in clinical trials. This limitation stems from the inherent structure of CDNs, which leads to enzymatic degradation, poor cell internalisation, rapid clearance from the tumour microenvironment, and dose-limiting toxicity.… Continue reading AlbiCDN： Albumin-binding Amphiphilic STING Agonists Augments the Immune Activity for Cancer Immunotherapy
[ASAP] Tumor-Targeted Delivery of PD-1-Displaying Bacteriophages by Escherichia coli for Adjuvant Treatment of Colorectal Cancer
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
Abstract Background The addition of immune checkpoint inhibitors to standard-of-care chemoradiation (CRT) is established as the new standard of care in high-risk, locally advanced cervical cancer. However, the optimal sequencing of therapies is unknown. Defining safety and feasibility of the combination was a primary objective of this study examining concurrent versus sequential schedules. Methods Pembrolizumab was given… Continue reading Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
Abstract Background The addition of immune checkpoint inhibitors to standard-of-care chemoradiation (CRT) is established as the new standard of care in high-risk, locally advanced cervical cancer. However, the optimal sequencing of therapies is unknown. Defining safety and feasibility of the combination was a primary objective of this study examining concurrent versus sequential schedules. Methods Pembrolizumab was given… Continue reading Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
Gene modification could improve cancer treatment’s success rate
A research team has made a major discovery on how the CUL5 gene affects CAR-T cell therapy, an advanced cancer therapy. The study reveals that reducing the activity of the CUL5 gene helps CAR-T cells fight cancer more effectively. These findings could improve immunotherapy for patients with aggressive cancers such as leukemia.